Early Treatment of Atrial Fibrillation for Stroke Prevention Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

2,789

Participants

Timeline

Start Date

July 1, 2011

Primary Completion Date

March 6, 2020

Study Completion Date

May 31, 2020

Conditions
Atrial FibrillationStroke
Interventions
OTHER

early standardised rhythm control

"Patients in the early therapy group will be treated following the same therapeutic recommendations of the ESC guidelines as the usual care group. In addition, rhythm control therapy will be initiated early with the aim of preventing recurrence and delaying or preventing progression of AF.~Early-onset rhythm control therapy can consist of:~1. Optimal antiarrhythmic drug therapy~2. Catheter ablation with the aim of pulmonary vein isolation (PVI),~3. Antiarrhythmic drug therapy and catheter ablation may be combined and supplemented by early cardioversion in patients with persistent AF.~All individual treatment decisions will be taken by the treating study physician considering the labelling of the procedures and drugs and patient preferences."

Trial Locations (11)

Unknown

14 Sites, Different

4 Sites, Different

2 Sites, Different

2 Sites, Different

51 Sites, Different

12 Sites, Different

13 Sites, Different

5 Sites, Different

10 Sites, Different

5 Sites, Different

22 Sites, Different

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

collaborator

Abbott

INDUSTRY

collaborator

The German Heart Foundation

OTHER

collaborator

European Heart Rhythm Association (EHRA)

UNKNOWN

collaborator

BMBF (German Ministry for Science)

UNKNOWN

collaborator

Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)

OTHER

lead

Atrial Fibrillation Network

OTHER